secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2025-06-05T23:59:59+00:00
Accession:  0001104659-25-056665
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa details Phase 2/3 trial design for KPL-387 in recurrent pericarditis; initiation mid-2025
--------------------------------------------------------------------------------

- Phase 2/3 trial: dose-focusing portion enrolls up to ~80 patients; pivotal portion up to ~85.
- Primary endpoint: time to treatment response at Week 24 (Phase 2) and time to first recurrence (Phase 3).
- Phase 1 single ascending dose data support monthly subcutaneous dosing with liquid formulation.
- Phase 2 data expected in second half of 2026.
- Corporate presentation at Jefferies 2025 Global Healthcare Conference at 12:50 pm ET on June 5.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000110465925056665/0001104659-25-056665-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000110465925056665/tm2517185d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-056665

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer